Myomo Reports Second Quarter 2022 Financial Results and Record Number of Patient Pipeline Additions

Rhea-AI Summary

Myomo reported a Q2 2022 revenue of $3.7 million, up 18% year-over-year, driven by a higher average selling price. The patient pipeline reached a record 1,049 candidates, marking a 52% increase. However, gross margin fell to 65.5%, down 550 basis points from last year, due to increased product costs. Despite these results, Myomo expects sequential growth in future quarters, though year-over-year revenue may decline in Q3 due to market conditions.

Positive

• Q2 2022 revenue of $3.7 million, up 18% from Q2 2021.
• Record 1,049 candidates in patient pipeline, up 52% year-over-year.
• Cost per pipeline addition decreased by approximately 50% over six months.

Negative

• Gross margin decreased to 65.5%, down 550 basis points year-over-year.
• Operating loss increased to $2.9 million in Q2 2022 compared to $2.6 million in Q2 2021.
• Delayed license payment from the joint venture partner in China due to COVID-19.

Second quarter revenue of $3.7 million up 18% over prior year

Cost per pipeline addition cut in half over the last six months

Conference call begins at 4:30 p.m. Eastern time today

BOSTON--(BUSINESS WIRE)-- Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and six months ended June 30, 2022.

Financial and operational highlights for the second quarter of 2022 include the following:

• Product revenue was $3.7 million, up 18% from Q2 2021 and up 28% sequentially;
• A record 420 new candidates were added to the patient pipeline, up 52% from Q2 2021 and resulting in 1,049 MyoPro® candidates overall in the pipeline as of June 30, 2022;
• MyoPro orders and insurance authorizations were received for 102 patients, bringing the total to 196 for the first half of 2022, compared with 204 in the first half of 2021;
• Direct billing channel represented 83% of revenue, compared to 73% in the prior year period, contributing to a higher average selling price (ASP);
• Revenue units were 80, in line with the prior year;
• Backlog, which represents insurance authorizations and orders received but not yet converted to revenue, was 163 units, up 2% from Q2 2021.
• Gross margin was 65.5%, down 550 basis points from Q2 2021 and down 120 basis points sequentially;
• Cost per pipeline add decreased 7% sequentially to approximately $2,470, approximately half the cost compared to Q4 2021; and
• As announced in July, the license payment from the Company's joint venture partner in China has been delayed due to the COVID-19 situation in China.

Management Commentary

“Patient pipeline growth was exceptional as we reduced advertising cost per new pipeline addition by approximately 50% over the last six months” stated Paul R. Gudonis, Myomo’s chairman and chief executive officer. “Our quarter-end patient pipeline stood at a record 1,049 candidates advancing through the insurance authorization process, which bodes well for future revenue. We're pleased with our financial results as the organization is tracking well against all major performance metrics."

"Progress with our joint venture in China has been impacted by restrictions imposed by the Chinese government in response to the ongoing COVID-19 outbreak," said Gudonis. "As a result, the balance of the license fee remains unpaid. Given the unpredictable nature of the pandemic, we cannot forecast when the final payment will be received and when we will begin providing any technology and know-how to support the start-up of the JV Company's operations."

Financial Results

	For the Three Months Ended June 30,						Period- to-Period Change						For the Six Months Ended June 30,						Period- to-Period Change
	2022			2021			$			%			2022			2021			$			%
Product revenue	$	3,677,575		$	3,104,294		$	573,281			18	%	$	6,545,501		$	5,440,783		$	1,104,718			20	%
License revenue		-			-			-		N/M				1,000,000			-			1,000,000		N/M
Total revenue		3,677,575			3,104,294			573,281			18	%		7,545,501			5,440,783			2,104,718			39	%
Cost of revenue		1,266,938			901,566			365,372			41	%		2,556,800			1,524,718			1,032,082			68	%
Gross profit	$	2,410,637		$	2,202,728		$	207,909			9	%	$	4,988,701		$	3,916,065		$	1,072,636			27	%
Gross margin %		65.5	%		71.0	%					-5.4	%		66.1	%		72.0	%					-5.9	%

Revenue for the second quarter of 2022 was $3.7 million, an increase of 18% compared with the second quarter of 2021. Growth in revenue was driven by a higher ASP. Myomo recognized revenue on 80 MyoPro units in the second quarter of 2022, unchanged from the same period a year ago. Year-to-date revenue of $7.5 million was up 39% compared with the same period a year ago. Excluding the partial joint venture license payment received in the first quarter of 2022, year to date product revenue of $6.5 million was up 20% compared to the same period a year ago.

Gross margin for the second quarter of 2022 was 65.5%, compared with 71.0% for the second quarter of 2021. The decrease was driven by higher product costs in the current inflationary environment, partially offset by a higher ASP. Year-to-date gross margin was 66.1%, compared with 72.0% in the year-ago period.

Operating expenses for the second quarter of 2022 were $5.3 million, an increase of 10% compared with the second quarter of 2021. The increase was driven primarily by higher compensation, payroll and advertising costs. Advertising costs of $1.0 million increased 34% compared to the second quarter of 2021. Year-to-date operating expenses were $10.6 million, an increase of 12% compared with the same period a year ago.

Operating loss for the second quarter of 2022 was $2.9 million compared to $2.6 million for the second quarter of 2021. Net loss for the second quarter of 2022 was $2.9 million, or $0.42 per share, compared with net loss of $2.6 million, or $0.46 per share, for the second quarter of 2021. Operating loss for the first six months of 2022 was $5.6 million, compared to $5.5 million for the same period a year ago. Net loss for the first six months of 2022 was $5.7 million, or $0.82 per share, compared with $5.6 million, or $1.03 per share for the same period a year ago.

Adjusted EBITDA for the first quarter of 2022 was negative $2.5 million, compared with negative $2.2 million for the second quarter of 2021. Adjusted EBITDA was a negative $4.9 million for both the six months ended June 30, 2022 and 2021. A reconciliation of GAAP net loss to this non-GAAP financial measure appears below.

Liquidity

Cash and cash equivalents as of June 30, 2022 were $10.2 million. Cash used in operating activities was $2.6 million for the second quarter of 2022. The Company entered into an equity line of credit ('ELOC") with Keystone Capital on August 2, 2022. The Company believes that its existing cash plus committed capital under the ELOC is sufficient to fund operations for at least the next 12 months.

Business Outlook

“Owing to our significant backlog, we are anticipating sequential growth in the third quarter and beyond,” said Gudonis. “While we are expecting lower year over year revenue in the third quarter, we remain confident that the accelerating pipeline is a better indicator of future revenue. We expect that the strong pipeline adds in the first half of this year will support continued growth over the next 12 months, while marketing and operational efficiencies are expected to improve our operating leverage in the coming quarters.”

Conference Call and Webcast Information

Myomo will hold a conference call today at 4:30 p.m. Eastern time to discuss these results and answer questions. Participants are encouraged to pre-register for the call [here]. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time including up to and after the start of the call. Those unable to pre-register may participate by dialing 844-707-6932 (U.S.) or 412-317-9250 (International). A webcast of the call will also be available at Myomo’s Investor Relations page at http://ir.myomo.com/.

A replay of the webcast will be available beginning approximately one hour after the completion of the live conference call at http://ir.myomo.com/. A dial-in replay of the call will be available until August 17, 2022 at 877-344-7529 (U.S.) or 412-317-0088 (International), with passcode 7111797.

Non-GAAP Financial Measures

Myomo is providing financial information that has not been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. This information includes Adjusted EBITDA. This non-GAAP financial measure is not in accordance with, or an alternative for, GAAP and may be different from similar non-GAAP financial measures used by other companies. Myomo believes the use of this non-GAAP financial measure provides supplementary information for investors to use in evaluating operating performance and in comparing Myomo’s financial measures with other companies in its industry, many of which present similar non-GAAP financial measures. Adjusted EBITDA is EBITDA adjusted for stock-based compensation expense. This non-GAAP financial measure is not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP, and should be viewed in conjunction with GAAP financial measures. Investors are encouraged to review the reconciliation of this non-GAAP measure to its most directly comparable GAAP financial measure. A reconciliation of GAAP to the non-GAAP financial measures has been provided in the tables included as part of this press release.

About Myomo

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Boston, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit www.myomo.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding the Company’s future business expectations, including expectations for in the third quarter, its objective of growing the authorization backlog and pipeline and its cash runway, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors.

These factors include, among other things:

• the direct and indirect impact of the novel coronavirus (COVID-19) on our business and operations, including fabrication and delivery, sales, patient consultations, supply chain, manufacturing, insurance reimbursements and employees;
• our ability to continue normal operations and patient interactions in order to deliver and fit our custom-fabricated device;
• our marketing and commercialization efforts;
• our ability to achieve reimbursement from third-party payers for our products;
• our dependence upon external sources for the financing of our operations, to the extent that we do not achieve or maintain cash flow breakeven;
• our ability to effectively execute our business plan and scale up our operations;
• our expectations as to our product development programs, and;
• general market, economic, environmental and social factors that may affect the evaluation, fitting, delivery and sale of our products to patients.

More information about these and other factors that potentially could affect our financial results is included in Myomo’s filings with the Securities and Exchange Commission, including those contained in the risk factors section of the Company’s annual report on Form 10-K, quarterly reports on Form 10-Q and other filings with the Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Although the forward-looking statements in this release of financial information are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes. No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material and adverse. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

(Tables to follow)

MYOMO, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
		Three Months Ended								Six Months Ended
		June 30,								June 30,
		2022				2021				2022				2021
Revenue
Product Revenue		$	3,677,575			$	3,104,294			$	6,545,501			$	5,440,783
License Revenue			—				—				1,000,000				—
			3,677,575				3,104,294				7,545,501				5,440,783
Cost of revenue			1,266,938				901,566				2,556,800				1,524,718
Gross profit			2,410,637				2,202,728				4,988,701				3,916,065
Operating expenses:
Research and development			632,872				600,116				1,292,408				1,126,083
Selling, general and administrative			4,664,088				4,202,244				9,320,505				8,322,047
			5,296,960				4,802,360				10,612,913				9,448,130
Loss from operations			(2,886,323	)			(2,599,632	)			(5,624,212	)			(5,532,065	)
Other (income) expense
Other (income) expense, including interest income, net			(4,174	)			6,018				(3,384	)			6,137
Loss on investment in minority interest			33,208				-				33,208				-
			29,034				6,018				29,824				6,137
Loss before income taxes			(2,915,357	)			(2,605,650	)			(5,654,036	)			(5,538,202	)
Income tax expense			(6,435	)			15,665				69,820				43,907
Net loss		$	(2,908,922	)		$	(2,621,315	)		$	(5,723,856	)		$	(5,582,109	)
Weighted average number of common shares outstanding:
Basic and diluted			6,923,799				5,639,524				6,904,966				5,416,708
Net loss per share attributable to common stockholders
Basic and diluted		$	(0.42	)		$	(0.46	)		$	(0.83	)		$	(1.03	)

MYOMO, INC. CONDENSED CONSOLIDATED BALANCE SHEETS
		June 30,				December 31,
		2022				2021
		(unaudited)
ASSETS
Current Assets:
Cash and cash equivalents		$	10,235,914			$	15,524,378
Accounts receivable, net			1,357,477				1,960,037
Inventories, net			1,260,936				808,308
Prepaid expenses and other current assets			451,100				799,164
Total Current Assets			13,305,427				19,091,887
Operating lease assets with right of use			695,933				632,906
Equipment, net			283,317				275,289
Investment in Jiangxi Myomo Medical Assistive Appliance Co. Ltd.			165,792				-
Other assets			111,034				95,330
Total Assets		$	14,561,503			$	20,095,412
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable and accrued expenses			3,445,339				3,949,784
Current operating lease liability			436,694				333,380
Deferred revenue			2,211				249
Total Current Liabilities			3,884,244				4,283,413
Deferred revenue, net of current portion			934				1,246
Non-current operating lease liability			328,729				401,622
Total Liabilities			4,213,907				4,686,281
Commitments and Contingencies			—				—
Stockholders’ Equity:
Preferred stock			—				—
Common stock			698				687
Additional paid-in capital			94,149,289				93,537,807
Accumulated other comprehensive loss			(9,849	)			(60,677	)
Accumulated deficit			(83,786,078	)			(78,062,222	)
Treasury stock, at cost			(6,464	)			(6,464	)
Total Stockholders’ Equity			10,347,596				15,409,131
Total Liabilities and Stockholders’ Equity		$	14,561,503			$	20,095,412

MYOMO, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
For the Six Months Ended June 30,		2022				2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		$	(5,723,856	)		$	(5,582,109	)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation			94,645				58,329
Stock-based compensation			611,493				529,283
Bad debt expense			26,075				—
Loss on disposal of asset			—				202
Amortization of right-of-use assets			162,638				66,653
Loss on equity investment			33,208				—
Other non-cash charges			69,521				1,772
Changes in operating assets and liabilities:			—				—
Accounts receivable			602,033				(194,455	)
Inventories			(496,529	)			(28,200	)
Prepaid expenses and other current assets			345,470				(426,749	)
Other assets			(15,704	)			—
Accounts payable and accrued expenses			(485,997	)			17,926
Operating Lease Liabilities			(195,244	)			54,983
Deferred revenue			1,650				(2,512	)
Other liabilities			—				(4,637	)
Net cash used in operating activities			(4,970,597	)			(5,509,514	)
CASH USED IN INVESTING ACTIVITIES			(301,672	)			(247,644	)
CASH PROVIDED BY FINANCING ACTIVITIES			-				7,289,483
Effect of foreign exchange rate changes on cash			(16,195	)			(1,122	)
Net (decrease) increase in cash, cash equivalents and restricted cash			(5,288,464	)			1,531,203
Cash, cash equivalents and restricted cash, beginning of period			15,524,378				12,241,261
Cash, cash equivalents and restricted cash, end of period		$	10,235,914			$	13,772,464

MYOMO, INC. RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA (unaudited)
		For the Three Months Ended June 30,								For the Six Months Ended June 30,
		2022				2021				2022				2021
GAAP net loss		$	(2,908,922	)		$	(2,621,315	)		$	(5,723,856	)		$	(5,582,109	)
Adjustments to reconcile to Adjusted EBITDA:
Interest (income) expense and other expense, net			(4,174	)			6,018				(3,384	)			6,137
Depreciation expense			49,015				35,016				94,645				58,329
Stock-based compensation			345,223				363,312				611,493				529,283
Loss on investment in minority interest			33,208				—				33,208				—
Income tax expense			(6,435	)			15,665				69,820				43,907
Adjusted EBITDA		$	(2,492,085	)		$	(2,201,304	)		$	(4,918,074	)		$	(4,944,453	)

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005720/en/

For Myomo:

ir@myomo.com



Investor Relations:

Kim Sutton Golodetz

LHA Investor Relations

kgolodetz@lhai.com

212-838-3777

Source: Myomo, Inc.

FAQ

What were Myomo's Q2 2022 financial results?

Myomo reported $3.7 million in revenue for Q2 2022, an 18% increase compared to Q2 2021.

How many candidates are in Myomo's patient pipeline as of June 30, 2022?

As of June 30, 2022, Myomo's patient pipeline reached a record 1,049 candidates.

What was Myomo's gross margin for Q2 2022?

Myomo's gross margin for Q2 2022 was 65.5%, down from 71.0% in the same period last year.

What is Myomo's outlook for the third quarter of 2022?

Myomo anticipates sequential growth in the third quarter, but expects lower year-over-year revenue.

What were Myomo's operating losses in Q2 2022?

Myomo reported an operating loss of $2.9 million for Q2 2022, compared to a $2.6 million loss in Q2 2021.